FDA Approves 1st Biosimilar But Punts On Naming Guidance
The U.S. Food and Drug Administration announced Friday it had approved Sandoz Inc.'s Zarxio, a copycat of Amgen Inc.'s anti-infection drug Neupogen, marking the first biosimilar allowed for use in the...To view the full article, register now.
Already a subscriber? Click here to view full article